Neurizon to present Q1 FY2026 Results
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Neurizon to present Q1 FY2026 Results to the Shareholders
31 October 2025 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the
Company”), a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to
announce an upcoming webinar presentation to provide shareholders with an update on the Company’s Q1 FY2026
results and recent progress in advancing NUZ-001 toward participation in the HEALEY ALS Platform Trial.
The presentation will outline the following:
Advancing NUZ-001 towards the HEALEY ALS Platform trial: successful submission and acceptance by the U.S. FDA
to lift the clinical hold, clearing the pathway for Neurizon’s entry into the trial.
Overview of synchronized regulatory strategy: continued execution of Neurizon’s regulatory strategy designed to
align U.S. FDA approval with global access across key markets.
Strengthened financial position: completion of a $5.2 million share placement with new and existing investors,
and receipt of $1.5 million from a secured loan against the FY2025 R&D Tax Incentive rebate.
Expanding global engagement: participation in leading industry conferences and scientific events to deepen
relationships with potential commercial partners, researchers, and the ALS patient community.
Anyone wishing to attend the webinar should register via the following link:
Registration: https://bit.ly/NUZ1025
Date and time: 1:00pm AEDT (10:00am AWST) on Friday, 31 October
Presentation slides are available as an attachment to this announcement. The recording of the presentation will be
made available on Neurizon’s website at www.neurizon.com.
-ENDS-
This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:
Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view
video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited.
ABN 35 094 006 023
Shareholder Update Webinar
Q1 FY 2026
31 October 2025
Disclaimer
This disclaimer applies to this presentation and the information contained in it (This presentation has been
prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the
information that a prospective investor may require in connection with any potential investment in the Company.
You should not treat the contents of this presentation, or any information provided in connection with it, as
financial advice, financial product advice or advice relating to legal, taxation or investment matters.
No representation or warranty (whether express or implied) is made by the Company or
any of its officers, advisers, agents or employees as to the accuracy, completeness or reasonableness of the
information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this
presentation or provided in connection with it, or any omission from this presentation, nor as to the attainability
of any estimates, forecasts or projections set out in this presentation.
This presentation is provided expressly on the basis that you will carry out your own independent inquiries into
the matters contained in the presentation and make your own independent decisions about the affairs, financial
position or prospects of the Company.
The Company reserves the right to update, amend or supplement the information at any time in its absolute
discretion (without incurring any obligation to do so).
Neither the Company, nor its related bodies corporate, officers, their advisers, agents and employees accept any
responsibility or liability to you or to any other person or entity arising out of this presentation including pursuant
to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and
Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any
corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any
other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the
maximum extent permitted by law, expressly disclaimed and excluded.
Nothing in this material should be construed as either an offer to sell or a solicitation of an offer to buy or sell
securities. It does not include all available information and should not be used in isolation as a basis to invest in
the Company.
Shareholder Update Webinar – Q1 FY2026 2
Future Matters
This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects
of the Company. Those intentions, expectations, future plans, strategy and prospects may or may not be
achieved. They are based on certain assumptions, which may not be met or on which views may differ and
may be affected by known and unknown risks. The performance and operations
of the Company may be influenced by a number of factors, many of which are outside the control of the
Company. No representation or warranty, express or implied, is made by the Company, or any of its
directors, officers, employees, advisers or agents that any intentions, expectations or plans will be achieved
either totally or partially or that any particular rate of return will be achieved.
Given the risks and uncertainties that may cause the Company’s actual future results, performance or
achievements to be materially different from those expected, planned or intended, recipients should not
place undue reliance on these intentions, expectations, future plans, strategy and prospects. The Company
does not warrant
or represent that the actual results, performance or achievements will be as expected, planned or intended.
US Disclosure
This document does not constitute any part of any offer to sell, or the solicitation of an offer to buy, any
securities in the United States or to, or for the account or benefit of any “US person” as defined in
Regulation S under the US Securities Act of 1993 (“Securities Act”). The Company’s shares have not been,
and will not be, registered under the Securities Act or the securities laws of any state or other jurisdiction of
the United States, and may not be offered or sold in the United States or to any US person without being so
registered or pursuant to an exemption from registration including an exemption for qualified institutional
buyers.
Shareholder Update Webinar – Q1 FY2026 3
1. Corporate Updates
2. Financial Snapshot
3. HEALEY ALS Platform Trial Update
4. Preclinical Development
5. Industry Engagement & Upcoming
Milestones
AGENDA
Dr Michael Thurn, Managing Director and Chief Executive Officer
Corporate Update
Q1 FY 2026 Highlights
Successfully raised
$5.2m through a
share placement
Shareholder Update Webinar – Q1 FY2026 5
Company Post-Quarter
Milestones:
• FDA opens IND for NUZ-001,
clearing the path to inclusion in
HEALEY ALS Platform Trial
• Common shares approved for
trading on the OTCQB®
• Australian patent granted for
NUZ-001
• Appointment of Integrous
Communications to strengthen
North American investor
engagement
Executed
Global License
Agreement
with Elanco
Submitted Clinical
Hold Complete
Response to FDA
First
registration
batch of
NUZ-001
Preliminary
R&D Funding
received
Top-line
results from
OLE study
PACTALS
conference and
presentation
R&D Tax
Incentive Advance
& Overseas Finding
Approval
Our regulatory strategy synchronises FDA approval with global market access, maximising commercial potential while addressing
the urgent needs of ALS patients worldwide.
FDA Accelerated Pathway
April 2025: PK Studies
Complete
Pharmacokinetic studies
concluded with exceptional
results, demonstrating >10×
safety margin at clinical dose
July 2025: CHCR
Submitted
Comprehensive Clinical Hold
Complete Response
submitted to FDA with
detailed safety data
October 2025: IND Opened
FDA’s decision to lift the
clinical hold received,
clearing the path to the
inclusion into the HEALEY Trial
November 2025:
Designation Applications
Designation applications to
further accelerate
development and
commercialisation
Q4 2025: HEALEY Trial
Entry
Synchronized Global Strategy
European Medicines Agency (EMA)
Orphan Drug Designation secured; regulatory consultation
aligned with FDA strategy for parallel review
Health Canada / Swissmedic
Regulatory timelines synchronized with FDA/EMA processes;
accelerated review pathways identified
PMDA (Japan) & TGA (Australia)
Japan consultation planned; Australia advancing Orphan Drug
and Provisional Approval strategies
Commercial readiness and new indication development (2027-2028) will
leverage our platform technology's potential across multiple
neurodegenerative diseases
Global Regulatory Strategy: Synchronised Approvals for Maximum
Impact
Shareholder Update Webinar – Q1 FY2026 6
Dan O’Connell, Chief Financial Officer
Financial Snapshot
Corporate Overview
8
Current Share Price (NUZ/NUZOA) $0.125/ $0.07
52 Week Low / High (NUZ) $0. 096/ $0.205
No. of Shares (NUZ) 1 534,555,765
Listed Options (NUZOA) 116,315,955
Market Capitalisation $66.8m
Cash (as at 30-Sep-25) $6.6m
Debt (as at 30-Sep-25)2 ($1.5m)
Net Cash $5.1m
Enterprise Value $61.7m
Unlisted Options
(10c/15c/17.5c/20c/26c/33.25c)
29.65m
Enterprise Value (fully diluted) $80.0m
Capital Structure (AUD$) 27 October 2025
Share Price Performance
Board & Management
Hybrid Holdings Pty Ltd <Darcy Family Super Fund A/C> 4.16%
Mr GJ & Mrs G Van Blommestein <Van Blommestein S/F A/C>
3.48%
Mr Chek Loon Tan 2.81%
Dr Roger Aston 2.53%
Board & Management 3.89%
Top Shareholders (as at 10 October 2025)
Mid-stage biotechnology company targeting human neurodegenerative diseases
Mr Sergio Duchini Chairman & Non-Executive Director
Dr Michael Thurn Chief Executive Officer & Managing Director
Mr Marcus Hughes Non-Executive Director
Dr Katie MacFarlane Non-Executive Director
Mr Dan O’Connell Chief Financial Officer
Mr Stefan Ross Company Secretary
Closing Price (AUD$) Volume (m)
1 Excludes 1,083,335 shares allocatedto Directors but subject to shareholder approval. Shareholder approval is being sought at the Annual General Meeting on 26 November 2025
2 Debt is a A$1.5m loan from Radium Capitalsecured against Australian R&D Rebate. SeeASX:NUZ “R&D Tax Incentive Advance & Overseas Finding Approval” 18 September 2025
-
1
2
3
4
5
6
0.00
0.10
0.20
0.30
0.40
0.50
27-Oct-24 27-Dec-24 27-Feb-25 27-Apr-25 27-Jun-25 27-Aug-25 27-Oct-25
Volume SP
Shareholder Update Webinar – Q1 FY2026
Commercial & Financial Update
Shareholder Update Webinar – Q1 FY2026 9
Financial Snapshot
• Cash balance of $6.6m at 30 September 2025
• Operating cash outflow of $3.7m - 17.5%
reduction on prior quarter.
• Executed a $1.5 million loan from Radium
Capital, secured against R&D Tax Rebate - an
important source of non-dilutive funding.
Continued spend reduction with additional funding to support strategic progress of Neurizon’s strategy
R&D Advance & Overseas Finding
• Advance and Overseas Finding awarded by
AusIndustry meaning eligible overseas R&D
expenditure with qualify for the rebate.
• Covers all NUZ-001 development activities -
manufacturing, regulatory and clinical -
including HEALEY ALS Platform Trial
• Binding on AusIndustry and the Australia
Taxation Office for 2025, 2026 and 2027
financial years.
• Supports Australian R&D Tax Rebate of
approximately $5.6m for FY2025.
Institutional Placement - $5m
• Raised $5.0m through a placement of at $0.12
per share
• Strong demand from new & existing investors,
with significant support from institutions
• Board and management committed a further
$0.2m in subscriptions, demonstrating support
for strategy
• Proceeds directed to advancing participation
in the HEALEY ALS Platform Trial, pre-clinical
programs, GMP manufacturing, regulatory
submissions, and working capital
requirements.
Dr Michael Thurn, Managing Director and Chief Executive Officer
Sharon Tamir, Clinical Development
Stacie Seidel, Translational Science & Patient Engagement
Josie Hayes, Translational Science
HEALEY ALS Platform Trial
Update
HEALEY ALS Platform Trial
NUZ-001 selected for entry into the HEALEY ALS Platform Trial
11
The HEALEY ALS Platform Trial is a competitive process led by a group of expert ALS scientists and members of the Healey & AMG Center Science Advisory
Committee
1. HEALEY ALS Platform Trial (https://www.massgeneral.org/neurology/als/research/platform-trial).
HEALEY ALS Platform Trial Design1
Patient Enrolls
in Platform
Trial
Active
Active
Active
Placebo
Placebo
Placebo
Placebo
Active
Active
Active
Placebo
Active
Active
Active
Placebo
Regimen H
Regimen I
Regimen J
Shared Placebo
Shared infrastructure and common
protocol, allowing sharing of
placebo participants
Randomization
Randomization
Randomization
Randomization
FDA approved Master Protocol
Design
• Shared master protocol
• >70 clinical sites across the US
• 3:1 active drug to placebo ratio
• 160 participants per regimen
• 7 regimens completed
• 2 regimens progressing to Phase 3
Innovative Trial Structure
NUZ-001
Primary Endpoint
Change from baseline through Week 36 in disease severity, measured by the
ALS Functional Rating Scale -Revised (ALSFRS-R) total score and survival.
Secondary Endpoints
Change from baseline through Week 36 in secondary efficacy measures (e.g., respiratory
function via slow vital capacity [SVC]
Survival through Week 36 (death or equivalent endpoint)
Shareholder Update Webinar – Q1 FY2026
“Regimen-I” HEALEY ALS Platform Key Milestones
Neurizon’s clinical hold
was lifted by the FDA on
October 3, 2025, clearing
the path to entry into the
HEALEY ALS Platform Trial
✓ 30% reduction in research costs
✓ 50% Faster
✓ 67% More Participants
✓ 160 participants
Enrollment Complete
Q3-Q4 2026
Q1 2026
4
5
First Patient Randomized
160 patients enrolled in the
trial
First patient screened for
eligibility
Last Patient Dosed
3
Q1 2026
First Patient Screened
6
NUZ-001 entry confirmed
Q2-Q3 2027
Last participant receives
final dose
Q4 2025
2
Database Lock
Q3 2027
FDA Clearance
7
Platform Trial IND submitted to
regulatory authorities
1
Clinical trial database locked
for analysis
Q4 2025
Topline Data Released
IND Amendment Submission
Topline results of the
trial announced
8 Q3 2027
First participant randomized
into treatment regimen
Shareholder Update Webinar – Q1 FY2026 12
Advancing Biomarker Strategy for in Ph2 HEALEY ALS Platform Trial
Unlock clinical and regulatory value to help accelerate approval and patient access
13
Shareholder Update Webinar – Q1 FY2026
We are developing a regimen-specific biomarker plan, using cutting-edge single-molecule and spatial multi-omics
technologies, to identify novel predictive and pharmacodynamic biomarkers beyond the HEALEY platform plan, ensuring
the most sensitive and relevant measures of clinical impact.
Biomarker What it Measures Rationale
NfL Axonal injury / neuronal degeneration
Sensitive, robust, validated in CSF & blood; strong prognostic &
pharmacodynamic value
p75ECD Ongoing axonal damage, higher levels may correlate with
disease progression
Ph1 MEND + OLE data suggest positive trends for patients on NUZ-
001, non-invasive urine testing
Priority Assays: Focus on Key Proteins in ALS
• Working alongside KOLs and clinical experts to develop and utilize additional assays:
• Protein assays testing key proteins in CSF and blood are being explored
• RNA Expression and Whole Genome Sequencing (WGS) are also options to dive in deeper to understand gene expression changes
• Innovative Digital Biomarker Strategy in Partnership with Redenlab
• Speech intelligibility in ALS is both a functional outcome (how well a person communicates) and a biological signal of disease
progression, making it highly relevant for patient care, prognosis, and clinical research.
Dr Jeffrey M Brown, Chief Scientific Advisor
Preclinical Development
Protein Aggregation and Reduced Protein Clearence are Drivers of
Neuronal Pathology in ALS
Shareholder Update Webinar – Q1 FY2026 15
TDP-43
aggregates
Transcriptional
dysregulation
Neuronal
damage
Autophagy Proteasome
TDP-43 aggregates
TDP-43 protein aggregation is a major driver of
neuronal damage in ALS
Protein aggregates block endogenous protein
clearance pathways
NUZ-001 Enhances Endogenous Protein Clearance Pathways to Remove
Toxic Protein Aggregates
Shareholder Update Webinar – Q1 FY2026 16
Enhanced clearance of TDP-
43 aggregates
Reduce
neuronal
damage
NUZ-001
NUZ-001 enters neuron and binds molecular
target
Enhance clearance of TDP-43 aggregates
Autophagy Proteasome
NUZ-001 enhances endogenous protein
clearance pathways
Restored
transcription
NUZ-001 Restored Brain-Derived Neurotrophic Factor (BDNF) Expression
and Reduced Brain Pathology in a Huntington's Disease Model
Shareholder Update Webinar – Q1 FY2026 17
DMSO NUZ-001 DMSO NUZ-001
0.0
0.2
0.4
0.6
0.8
1.0
Relative
Expression
(ΔΔCt)
BDNF Expression
Normal Huntington
Knockdown
✱✱
DMSO NUZ-001 DMSO NUZ-001
0.0
0.5
1.0
1.5
2.0
Brain Swelling
Severity
Score
Normal Huntington
Knockdown
✱
✱✱
✱✱
Preclinical Data Continues to Inform Biology of NUZ-001 for ALS and Other
Neurodegenerative Diseases
NUZ-001:
Shareholder Update Webinar – Q1 FY2026 18
Reduces TDP-43 aggregation
in a human neuronal model
of ALS
Crosses the the blood brain
barrier
Achieves brain levels that are
physiologically relevant based on
preclinical studies
Decreases p62 levels, consistent
with activation of autophagy in
normal and Huntington's disease
human neuronal models
Restores expression of a critical
neurotrophic factor (Brain Derived
Neurotrophic Factor) in a Zebra
Fish model of Huntington's
disease
Reverse deficits-induced by loss
of the huntingtin protein in a
Zerba fish model of Huntington's
Disease.
Dr Michael Thurn, Managing Director and Chief Executive Officer
Industry and Patient
Engagement &
Upcoming Milestones
Driving Impact Through Global Collaboration and Engagement
Shareholder Update Webinar – Q1 FY2026 20
Engaging with investors through global
roadshows and strategic summits, including
HealthInvest, BioJapan and Ignite Summit.
Represented at leading ALS and
neurodegenerative research
conferences, including NEALS and
PACTALS.
Championing a patient-driven mission that
keeps people living with ALS at the centre
of everything we do.
Upcoming Industry Engagements
• USA Investor Roadshow (October 29-31)
• ALS Association Roundtable (November 13, DC, USA)
• The Annual Society of Neuroscience Conference (November 15-19, CA, USA)
• 36th International Symposium on ALS/MND (December 5-7, CA, USA)
• JP Morgan Healthcare Conference (January 12-15, CA, USA)
Shareholder Update Webinar – Q1 FY2026 21
Neurizon remains focused on expanding its global presence
Advancing awareness, forging strategic partnerships, and engaging with the
broader scientific and patient communities.
Near Term Milestones
22
Q2 Q3
FY
2026
ONGOING EFFORTS
• 43rd J.P. Morgan Annual Healthcare Conference
• HEALEY ALS Platform Trial– Site Activation
• Additional Preclinical Updates
• EMA Scientific Advice meeting
• Ethics Approval for Liquid Formulation PK Study
• HEALEY ALS Platform Trial – First Patient Dosed
✓US FDA lifts clinical hold
✓NEALS Annual Conference Meeting Presentations
✓Commenced trading on OTCQB
✓Australian Patent granted for NUZ-001
• Additional Preclinical Updates
• Completion of Second and Third registration batches of NUZ-001
• Supply Agreement with Elanco
• Australian R&D Refund (net of R&D funding)
• HEALEY Submits NUZ-001 Protocol Amendment to US FDA for Platform Trial
• FDA’s Confirmation of Entry into HEALEY ALS Platform Trial
• 36th International Symposium on ALS/MND
• FDA Fast Track Designation for NUZ-001
✓ Work to broaden pipeline to other
neurodegenerative diseases
✓ Partnership expansion opportunities with
patient associations
✓ Targeted engagement with
potential strategic partners
Significant near-term news flow drive value and growth
Shareholder Update Webinar – Q1 FY2026
Registered Address:
Suite 2, 385 Bourke Street
Melbourne, VIC 3000 Australia
+61 (3) 9692 7222
enquiries@neurizon.com
THANK YOU
Share your feedback
Discover